Medactive Oral Relief
Lozenge
Integrate Oral Care, Llc.
Human Otc Drug
NDC 49741-1009Medactive Oral Relief also known as Lozenge is a human otc drug labeled by 'Integrate Oral Care, Llc.'. National Drug Code (NDC) number for Medactive Oral Relief is 49741-1009. This drug is available in dosage form of Lozenge. The names of the active, medicinal ingredients in Medactive Oral Relief drug includes Pectin - 2.8 mg/1 . The currest status of Medactive Oral Relief drug is Active.
Drug Information:
| Drug NDC: | 49741-1009 |
| The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC. |
| Proprietary Name: | Medactive Oral Relief |
| Also known as the trade name. It is the name of the product chosen by the labeler. |
| Product Type: | Human Otc Drug |
| Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. |
| Non Proprietary Name: | Lozenge |
| Also known as the generic name, this is usually the active ingredient(s) of the product. |
| Labeler Name: | Integrate Oral Care, Llc. |
| Name of Company corresponding to the labeler code segment of the ProductNDC. |
| Dosage Form: | Lozenge |
| The translation of the DosageForm Code submitted by the firm. There is no standard, but values may include terms like `tablet` or `solution for injection`.The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources. |
| Status: | Active |
| FDA does not review and approve unfinished products. Therefore, all products in this file are considered unapproved. |
| Substance Name: | PECTIN - 2.8 mg/1
|
| This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted. |
| Route Details: | ORAL
|
| The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
Marketing Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Marketing Category: | OTC MONOGRAPH NOT FINAL |
| Product types are broken down into several potential Marketing Categories, such as New Drug Application (NDA), Abbreviated New Drug Application (ANDA), BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources. |
| Marketing Start Date: | 31 Aug, 2015 |
| This is the date that the labeler indicates was the start of its marketing of the drug product. |
| Marketing End Date: | 23 Dec, 2025 |
| This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached. |
| Application Number: | part356 |
| This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null. |
| Listing Expiration Date: | 31 Dec, 2023 |
| This is the date when the listing record will expire if not updated or certified by the firm. |
OpenFDA Information:
An openfda section: An annotation with additional product identifiers, such as NUII and UPC, of the drug product, if available.
| Manufacturer Name: | Integrate Oral Care, LLC.
|
| Name of manufacturer or company that makes this drug product, corresponding to the labeler code segment of the NDC. |
| RxCUI: | 637146
|
| The RxNorm Concept Unique Identifier. RxCUI is a unique number that describes a semantic concept about the drug product, including its ingredients, strength, and dose forms. |
| Original Packager: | Yes
|
| Whether or not the drug has been repackaged for distribution. |
| UNII: | 89NA02M4RX
|
| Unique Ingredient Identifier, which is a non-proprietary, free, unique, unambiguous, non-semantic, alphanumeric identifier based on a substance’s molecular structure and/or descriptive information. |
Packaging Information:
| Package NDC | Description | Marketing Start Date | Marketing End Date | Sample Available |
|---|
| 49741-1009-2 | 20 CELLO PACK in 1 BOX (49741-1009-2) / 1 LOZENGE in 1 CELLO PACK (49741-1009-1) | 31 Aug, 2015 | N/A | No |
| Package NDC number, known as the NDC, identifies the labeler, product, and trade package size. The first segment, the labeler code, is assigned by the FDA. Description tells the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. |
Purpose:
Purpose oral demulcent
Product Elements:
Medactive oral relief lozenge malic acid pectin pectin acesulfame potassium dimethicone isomalt poloxamer 338 sucralose water citric acid acetate fd&c yellow no. 5 none lemonlime
Indications and Usage:
Uses for temporary relief of minor discomfort and protection of irritated areas in sore mouth and sore throat.
Warnings:
Warnings: sore throat warning: if sore throat is severe, persists for more than 2 days, is accompanied or followed by fever, headache, rash, nausea, or vomiting, consult a doctor promptly. if sore mouth symptoms do not improve in 7 days, see your dentist or doctor promptly.
Dosage and Administration:
Directions use as needed, up to 8 lozenges per day, or as directed by a dentist or doctor. adults and children 2 years of age and older: allow lozenge to dissolve slowly in the mouth. for optimal effect, intermittently position lozenge under the tongue. do not swallow whole. do not chew. children under 12 years of age: should be supervised in the use of this product. children under 2 years of age: consult a dentist or doctor.
Package Label Principal Display Panel:
Medactive® oral relief lozenges for relief of oral discomfort with ultramulsion® & spilanthes extract lemonlime oral demulcent pectin 2.8mg ndc 49741-1009-2 20 lozenges lozenge lemonlime
Further Questions:
Questions? call toll-free 1-866-887-4867 or visit www.integrateoralcare.com